Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 288 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cystic Fibrosis patients Clear all
Recruiting No phase listed Observational

Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome

NCT05982795
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge, Olfactory Function Testing, Survey Completion
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated No phase listed Observational

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

NCT01652157
View directory record Official record
Conditions
Fibrosing Colonopathy
Interventions
ULTRESA, PANCREAZE, CREON, ZENPEP, other non-sponsor pancreatic enzyme replacement therapy, PERTZYE, No pancreatic enzyme replacement therapy
Biological · Other
Lead sponsor
AbbVie
Industry
Eligibility
0 Months to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
123
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

NCT01641822
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI, Placebo to match AZLI, Tobramycin inhalation solution
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Not applicable Interventional

Implementation of a Clinical Tool to Improve Waitlist Mortality in Patients With Cystic Fibrosis

NCT04687475
View directory record Official record
Conditions
Cystic Fibrosis, Lung Transplant; Complications
Interventions
Clinical Tool (Mobile Spirometry and Survey)
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational

Comparing Expectorated and Induced Sputum and Pharyngeal Swabs for Cultures, AFB Smears, and Cytokines in Pulmonary Nontuberculous Mycobacterial Infection

NCT01150721
View directory record Official record
Conditions
Mycobacterium Infections, Non-tuberculous
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 80 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis

NCT02444234
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tedizolid PO, Tedizolid IV
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Phase 3 Interventional Results available

Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis

NCT02456103
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 2, 2026, 4:11 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

NCT04467957
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Initiation of CFTR Modulator, Hyperpolarized Xenon 129
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Not applicable Interventional Results available

Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

NCT02598128
View directory record Official record
Conditions
Exocrine Pancreatic Insufficiency
Interventions
RELiZORB, Placebo
Device
Lead sponsor
Alcresta Therapeutics, Inc.
Industry
Eligibility
4 Years to 45 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Boise, Idaho • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational Results available

STeP IT UP CF: STimulating ImProved Health And Well-being In CysTic Fibrosis

NCT04018495
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 100 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Not applicable Interventional

Exercise Training Study for Patients With Cystic Fibrosis

NCT00609050
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Self-Regulated Exercise with Telephone Reinforcement, Standard Treatment, Qualitative Approach
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
10 Years to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Absorptive Clearance in the Cystic Fibrosis Airway

NCT00541190
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)

NCT02354859
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Gallium nitrate, Normal Saline
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Oct 2, 2026, 4:11 AM EDT
Active, not recruiting Phase 4 Interventional

Hyperpolarized Imaging for New Treatments

NCT04259970
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Initiation of CFTR Modulator
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Cincinnati, Ohio • Charlottesville, Virginia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Phase 2 Interventional Results available

Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients

NCT02170025
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Birmingham, Alabama • Denver, Colorado • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 1 Interventional Results available

A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients

NCT01093521
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
100 mg/m2 dose, 200 mg/m2 dose
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA

NCT00585364
View directory record Official record
Conditions
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational

Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy

NCT01858519
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 99 Years
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
47
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Long Beach, California + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 2 Interventional

Glutamine Supplementation in Cystic Fibrosis

NCT01051999
View directory record Official record
Conditions
Cystic Fibrosis, Immune Function
Interventions
Glutamine, L-alanine
Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational

Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerb. in Patients With CF

NCT02109822
View directory record Official record
Conditions
Cystic Fibrosis, Lung Infection, Cystic Fibrosis Pulmonary Exacerbation
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
12 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Birmingham, Alabama • Tucson, Arizona • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Phase 3 Interventional Results available

Study of Ataluren (PTC124) in Cystic Fibrosis

NCT02107859
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
7
States / cities
Birmingham, Alabama • Long Beach, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Not applicable Interventional

Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis

NCT00004489
View directory record Official record
Conditions
Osteoporosis, Cystic Fibrosis
Interventions
alendronate sodium, calcium carbonate, cholecalciferol
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

Feasibility of Home-based Exercise Program for Adults With Cystic Fibrosis

NCT05239611
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Xenon MRI
Diagnostic Test
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Phase 4 Interventional Results available

Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles

NCT02015663
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Tobramycin Inhalation Powder
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
21
States / cities
Mobile, Alabama • Los Angeles, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 2, 2026, 4:11 AM EDT